Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes
Diabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first-line therapies in selected instances, as per the updated ADA guidelines, highlighting their...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/cjid/6675676 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832088005573083136 |
|---|---|
| author | Jie Luo Yilin Fang Zhanghua Qi Fengyang Cui Hong Hu Shengjie Li Tingtao Chen Hongyan Zhang |
| author_facet | Jie Luo Yilin Fang Zhanghua Qi Fengyang Cui Hong Hu Shengjie Li Tingtao Chen Hongyan Zhang |
| author_sort | Jie Luo |
| collection | DOAJ |
| description | Diabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first-line therapies in selected instances, as per the updated ADA guidelines, highlighting their efficacy not only in glycemic control but also in their broader health benefits. Nonetheless, the efficacy of GLP-1 is limited by its brief duration of action, rapid clearance from the body, and challenges associated with subcutaneous administration. In this study, we examined the potential diabetes-mitigating effects of a genetically engineered strain of Escherichia coli Nissle 1917 (EcN)-GLP-1, previously developed by our group. We utilized mouse models for both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) to assess its efficacy. In the case of T1DM mice, the results revealed that EcN-GLP-1 resulted in a notable decrease in blood glucose levels. Furthermore, it exhibited a protective influence on the structural integrity of islet β-cells; downregulated the expressions of key inflammatory markers such as TLR-4, p-NF-κB/NF-κB, and Bax/Bcl-2; promoted the insulin secretion; and reinstated the perturbed diversity of microbial species to a normal state. Similarly, EcN-GLP-1 had a pronounced impact on T2DM mice, manifesting increased presence of islet β-cells, decreased inflammatory response and apoptosis, and regulation of lipid metabolism in the liver. In summary, the genetically modified EcN-GLP-1 strain demonstrates the ability to alleviate diabetes by enhancing the islet β-cell population, mitigating inflammatory reactions and apoptosis, optimizing liver lipid metabolism, and reinstating a balanced microbial diversity. These findings hold promise as a potential avenue for treating DM. |
| format | Article |
| id | doaj-art-7733f3f5256148ecacec67e0ee313527 |
| institution | Kabale University |
| issn | 1918-1493 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases and Medical Microbiology |
| spelling | doaj-art-7733f3f5256148ecacec67e0ee3135272025-02-06T00:00:03ZengWileyCanadian Journal of Infectious Diseases and Medical Microbiology1918-14932025-01-01202510.1155/cjid/6675676Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 DiabetesJie Luo0Yilin Fang1Zhanghua Qi2Fengyang Cui3Hong Hu4Shengjie Li5Tingtao Chen6Hongyan Zhang7Jiangxi Provincial Key Laboratory of Disease Prevention and Public HealthNational Engineering Research Center for Bioengineering Drugs and the TechnologiesNational Engineering Research Center for Bioengineering Drugs and the TechnologiesNational Engineering Research Center for Bioengineering Drugs and the TechnologiesNational Engineering Research Center for Bioengineering Drugs and the TechnologiesNational Engineering Research Center for Bioengineering Drugs and the TechnologiesNational Engineering Research Center for Bioengineering Drugs and the TechnologiesMedical Center of Burn Plastic and Wound RepairDiabetes mellitus (DM) is a persistent and steadily progressing metabolic condition distinguished by unregulated high levels of blood glucose. GLP1 receptor agonists have recently gained recognition as first-line therapies in selected instances, as per the updated ADA guidelines, highlighting their efficacy not only in glycemic control but also in their broader health benefits. Nonetheless, the efficacy of GLP-1 is limited by its brief duration of action, rapid clearance from the body, and challenges associated with subcutaneous administration. In this study, we examined the potential diabetes-mitigating effects of a genetically engineered strain of Escherichia coli Nissle 1917 (EcN)-GLP-1, previously developed by our group. We utilized mouse models for both Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM) to assess its efficacy. In the case of T1DM mice, the results revealed that EcN-GLP-1 resulted in a notable decrease in blood glucose levels. Furthermore, it exhibited a protective influence on the structural integrity of islet β-cells; downregulated the expressions of key inflammatory markers such as TLR-4, p-NF-κB/NF-κB, and Bax/Bcl-2; promoted the insulin secretion; and reinstated the perturbed diversity of microbial species to a normal state. Similarly, EcN-GLP-1 had a pronounced impact on T2DM mice, manifesting increased presence of islet β-cells, decreased inflammatory response and apoptosis, and regulation of lipid metabolism in the liver. In summary, the genetically modified EcN-GLP-1 strain demonstrates the ability to alleviate diabetes by enhancing the islet β-cell population, mitigating inflammatory reactions and apoptosis, optimizing liver lipid metabolism, and reinstating a balanced microbial diversity. These findings hold promise as a potential avenue for treating DM.http://dx.doi.org/10.1155/cjid/6675676 |
| spellingShingle | Jie Luo Yilin Fang Zhanghua Qi Fengyang Cui Hong Hu Shengjie Li Tingtao Chen Hongyan Zhang Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes Canadian Journal of Infectious Diseases and Medical Microbiology |
| title | Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes |
| title_full | Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes |
| title_fullStr | Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes |
| title_full_unstemmed | Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes |
| title_short | Administration of a Next-Generation Probiotic Escherichia coli Nissle 1917-GLP-1 Alleviates Diabetes in Mice With Type 1 and Type 2 Diabetes |
| title_sort | administration of a next generation probiotic escherichia coli nissle 1917 glp 1 alleviates diabetes in mice with type 1 and type 2 diabetes |
| url | http://dx.doi.org/10.1155/cjid/6675676 |
| work_keys_str_mv | AT jieluo administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes AT yilinfang administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes AT zhanghuaqi administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes AT fengyangcui administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes AT honghu administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes AT shengjieli administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes AT tingtaochen administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes AT hongyanzhang administrationofanextgenerationprobioticescherichiacolinissle1917glp1alleviatesdiabetesinmicewithtype1andtype2diabetes |